MX2021013715A - ENSAYO MULTIPLEX PARA DETERMINAR LA PROPORCION DE ß-AMILOIDE 42/40 EN MUESTRAS DE PLASMA HUMANO. - Google Patents

ENSAYO MULTIPLEX PARA DETERMINAR LA PROPORCION DE ß-AMILOIDE 42/40 EN MUESTRAS DE PLASMA HUMANO.

Info

Publication number
MX2021013715A
MX2021013715A MX2021013715A MX2021013715A MX2021013715A MX 2021013715 A MX2021013715 A MX 2021013715A MX 2021013715 A MX2021013715 A MX 2021013715A MX 2021013715 A MX2021013715 A MX 2021013715A MX 2021013715 A MX2021013715 A MX 2021013715A
Authority
MX
Mexico
Prior art keywords
amyloid
determining
ratio
human plasma
multiplex assay
Prior art date
Application number
MX2021013715A
Other languages
English (en)
Inventor
Keith R Morneau
Brian G Sansoucy
Original Assignee
Quest Diagnostics Invest Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quest Diagnostics Invest Llc filed Critical Quest Diagnostics Invest Llc
Publication of MX2021013715A publication Critical patent/MX2021013715A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/34—Purifying; Cleaning
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente tecnología se refiere a métodos para diagnosticar, controlar la progresión, evaluar la eficacia del tratamiento o evaluar el riesgo de desarrollo de un trastorno neurodegenerativo en un paciente. Estos métodos se basan en determinar la proporción de ß-amiloide 42 ("Aß42") a ß-amiloide 40 ("Aß40") en una muestra de fluido recolectada de un paciente quien tiene o se sospecha que tiene un trastorno neurodegenerativo, usando un ensayo de proteína multiplex mejorado y altamente sensible que simultáneamente detecta Aß42 y Aß40.
MX2021013715A 2019-05-10 2020-05-08 ENSAYO MULTIPLEX PARA DETERMINAR LA PROPORCION DE ß-AMILOIDE 42/40 EN MUESTRAS DE PLASMA HUMANO. MX2021013715A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962846565P 2019-05-10 2019-05-10
PCT/US2020/032010 WO2020231774A1 (en) 2019-05-10 2020-05-08 MULTIPLEX ASSAY FOR DETERMINING THE ß-AMYLOID 42/40 RATIO IN HUMAN PLASMA SPECIMENS

Publications (1)

Publication Number Publication Date
MX2021013715A true MX2021013715A (es) 2022-01-24

Family

ID=73289510

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013715A MX2021013715A (es) 2019-05-10 2020-05-08 ENSAYO MULTIPLEX PARA DETERMINAR LA PROPORCION DE ß-AMILOIDE 42/40 EN MUESTRAS DE PLASMA HUMANO.

Country Status (7)

Country Link
US (1) US20220260592A1 (es)
EP (1) EP3966572A4 (es)
CN (1) CN114072678A (es)
BR (1) BR112021022421A2 (es)
CA (1) CA3139530A1 (es)
MX (1) MX2021013715A (es)
WO (1) WO2020231774A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ516848A (en) * 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
US20110091910A1 (en) * 2009-09-18 2011-04-21 Probiodrug Ag Novel assay
WO2011070174A1 (en) * 2009-12-11 2011-06-16 Araclon Biotech, S.L. Methods and reagents for improved detection of amyloid beta peptides
US20140094386A1 (en) * 2011-04-12 2014-04-03 David Wilson Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury resulting from a hypoxic event
EP2511296A1 (en) * 2011-04-12 2012-10-17 Araclón Biotech, S. L. Antibody, kit and method for determination of amyloid peptides
US20180003703A1 (en) * 2015-01-13 2018-01-04 Quanterix Corporation Methods relating to improving accuracy of capture object-based assays

Also Published As

Publication number Publication date
WO2020231774A1 (en) 2020-11-19
EP3966572A1 (en) 2022-03-16
EP3966572A4 (en) 2023-01-25
US20220260592A1 (en) 2022-08-18
CA3139530A1 (en) 2020-11-19
CN114072678A (zh) 2022-02-18
BR112021022421A2 (pt) 2021-12-28

Similar Documents

Publication Publication Date Title
Lauridsen et al. Critical flicker frequency and continuous reaction times for the diagnosis of minimal hepatic encephalopathy. A comparative study of 154 patients with liver disease
ATE423217T1 (de) Assays zur überwachung von krebspatienten auf grundlage der spiegel von analytenkomponenten des plasminogen-aktivator-systems in proben von körperflüssigkeiten
JP2011510309A5 (es)
DE60329165D1 (de) Detektion und/oder beobachtung von synuclein-assoziierten krankheiten
WO2003107252A3 (en) METHOD AND SYSTEM FOR MONITORING PATIENT CARE
BRPI0506752A (pt) sistema ou método para avaliar a circulação de sangue periférica de um indivìduo
ATE514948T1 (de) In vitro verfahren zur diagnose von neurodegenerativen erkrankungen
NZ601022A (en) Diagnosis and treatment of cancer using anti-ereg antibody
AR048031A1 (es) Metodos para estimar la necesidad y efectividad de la terapia con antioxidantes
AU2011241174B2 (en) Method and kit for cancer diagnosis
MX2020009278A (es) Ensayos para detectar la neurodegeneración.
TR199902828T2 (xx) Lizofosfolipidlerin de�i�mi� konsantrasyonlar� ile birle�tirilmi� kanser belirleme y�ntemi.
DE60137264D1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
WO2007015113A3 (en) New protein isoforms of the pif-family and uses thereof
ATE415632T1 (de) Verfahren zur diagnose und behandlung von morbus crohn
MX2021013715A (es) ENSAYO MULTIPLEX PARA DETERMINAR LA PROPORCION DE ß-AMILOIDE 42/40 EN MUESTRAS DE PLASMA HUMANO.
BR112015021507A8 (pt) métodos e composições para o diagnóstico de pré-eclampsia em uma mulher grávida e kit de ensaio de diagnóstico
NZ512768A (en) Diagnostic test to detect IV cytosolic phospholipase A2 (cPLA2)
EP0563244A4 (en) Human phospholipase activating protein and methods for diagnosis of rheumatoid arthritis
MX2022011632A (es) Anticuerpos contra mucina 17 y usos de los mismos.
MX2022004017A (es) Deteccion de analitos por medio de interruptores de proteinas.
CN112240932A (zh) 肺癌患者尿液表达的kng1蛋白的应用
JP6422161B2 (ja) ＩｇＡ腎症検査法
SG11201901435UA (en) Monoclonal antibody against melk and utilization thereof
TWI631339B (zh) Using WISP1 concentration in blood as a method for screening and detecting recurrence of breast cancer